Modern is consistent with the literature in this space, but the trial shows that a staged complete procedure might be just ...

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The intracoronary fibrinolysis infusion joins a host of other failed treatments to improve microvascular obstruction after ...

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

The DCB is meant to address long-term stent-related complications and avoid adding yet another metal layer in ISR.

“Cutting balloon angioplasty is a reasonable and less costly option when compared with intravascular lithotripsy for the ...

The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.

The real-world Evoque and new TRILUMINATE findings provide an “extension” from the pivotal trials, Dharam Kumbhani says.

Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.